<DOC>
	<DOC>NCT02795273</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of Grass-SPIRE compared with placebo and to evaluate the treatment effect of Grass-SPIRE on symptoms and use of rescue medication during the grass pollen season</brief_summary>
	<brief_title>Efficacy and Safety of Grass-SPIRE Registration Study</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Clinical history of grass polleninduced allergic rhinitis with or without conjunctivitis for at least 2 years Score of ≤ 21 on RCAT questionnaire Rye grass specific IgE of ≥ 0.7 kU/L Positive skin prick test to Rye grass whole allergen extract History or findings of significant disease Asthma requiring GINA Step 3 or higher treatment History of severe drug allergy, severe angioedema or systemic allergic reaction Course of shortduration allergyspecific immunotherapy or more than 3 months treatment with longduration allergen immunotherapy within 5 years Contraindications for administration of epinephrine</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Conjunctivitis</keyword>
	<keyword>Grass</keyword>
	<keyword>Allergy</keyword>
</DOC>